Thrilled to share our preprint around using causal machine learning to reduce placebo response in neuropsychiatric clinical trials – this new direction of scientific research has probably been as far from functional genomics as you can get :) www.medrxiv.org/content/10.6... (1/n)
Reducing placebo response in clinical trials of agitation in Alzheimer’s disease
High placebo response is an obstacle in developing drugs to treat agitation in Alzheimer’s disease (AAD), a prevalent and burdensome symptom. However, it has proved challenging to develop actionable m...
medrxiv.org
